New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients
Recruiting · NCT02808572 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Montpellier
View the official record on ClinicalTrials.gov →Interventions studied
Plasma fibroblast growth factor 23 levelPlasma osteoprotegerin levelVascular calcification score
What this trial is about
To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.
Who can take part
Age range
18 Years to 95 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patient who has signed the written consent form
- Patient with chronic renal failure defined by glomerular filtration rate (GFR) but without dialysis therapy
Exclusion criteria
- Pregnancy
- Patient with chronic renal failure requiring dialysis therapy
Where it is running
7 locations listed.
- AIDER - Montpellier, France
- CHU Montpellier, Cardiology department - Montpellier, France
- CHU Montpellier, Endocrinology department - Montpellier, France
- CHU Montpellier, Intensive care unit - Montpellier, France
- CHU Montpellier, Internal medicine department - Montpellier, France
- CHU Montpellier, Nephrology department - Montpellier, France
- AIDER - Saint-Jean-de-Védas, France